Sort
78,016 grants matching “breast cancer”
Beaumont Community Clinical Oncology Program
$830,438William Beaumont Hospital Research Inst · U10 · FY2004 · CA
Cell and Chemical Biology of Microtubules
$830,198Timothy J Mitchison · Harvard Medical School · R35 · FY2022 · GM
Structural studies of molecular targets for drug development
$830,189David S Waugh · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Investigating the Roles of Patient Beliefs, Stigma, and Physician Implicit Bias on Disparities in Lung Cancer Screening
$829,937Minal S Kale · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · MD
Investigating the Roles of Patient Beliefs, Stigma, and Physician Implicit Bias on Disparities in Lung Cancer Screening
$829,767Minal S Kale · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · MD
Breast Cancer Survivors Cardiovascular Risks: Treatment and Behavioral Influences
$829,667Janice K Kiecolt-Glaser · Ohio State University · R01 · FY2014 · CA
SINGAPORE COHORT STUDY OF DIET AND CANCER
$829,658University Of Southern California · R01 · FY2000 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
$829,650Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2018 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
$829,650Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2022 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
$829,650Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2020 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
$829,650Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2019 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
$829,650Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2021 · CA
Regulation of CTCF Functions and Target Sites by Cancer/Testis-specific CTCF Like BORIS Factor
$829,516Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Discovery, Biology and Risk of Inherited Variants in Glioma
$829,381Melissa L Bondy · Stanford University · R01 · FY2023 · CA
A Randomized Trial of Physical Activity for Cognitive Functioning in Breast Cancer Survivors
$829,364Sheri J Hartman · University Of California, San Diego · R01 · FY2023 · CA
Endogenous hormones and postmenopausal breast cancer: Etiologic insights and improving risk prediction
$829,291Susan E. Hankinson · University Of Massachusetts Amherst · R01 · FY2019 · CA
Next Generation Sequencing for Disease Mapping in a Founder Population
$829,164Todd Lencz · Feinstein Institute For Medical Research · R01 · FY2016 · MH
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
$829,068Brian L Sprague · University Of Vermont & St Agric College · R01 · FY2025 · CA
Simulating Protein Structures, Complexes, And Dynamics
$829,041Peter J Steinbach · Center For Information Technology · ZIA · FY2009 · CT
Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
$829,004Joan M Lappe · Creighton University · R01 · FY2009 · CA
Molecular Programs Governing Enterococcal Translocation
$828,820Diana K. Morales · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · AI
Identification of Inhibitors of Protein Sumoylation
$828,643John Schneekloth · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
NY-ESO-1-SPECIFIC TCR-ENGINEERED T CELL IMMUNOTHERAPY FOR TRIPLE NEGATIVE BREAST CANCER
$828,577The Methodist Hospital Research Institute · · FY2016 · Defense Health Agency
Interaction of Radiation, BRCA1/2, and Breast Cancer
$828,511Jonine Lisa Bernstein · Sloan-Kettering Inst Can Research · R01 · FY2006 · CA
Etiologic Studies of Prostate Cancer
$828,439Demetrius Albanes · Division Of Cancer Epidemiology And Genetics · ZIA · FY2019 · CA